Hutchison China Meditech Starts HMPL-523 Trial In China
(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last Read More